Arkolith/Insider Trading/BBIO/Form 4

Ellis Andrea

DirectorBridgeBio Pharma, Inc. (BBIO) · full profile →Form 4 · filed Jul 13, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.4M
Net Open-Market Flow
-$1.4M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 9, 2026Option exercise(M)17K$16.75$288K40K
Jul 9, 2026Sell(S)17K$84.00$1.4M23K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 9, 2026Option exercise(M)17K—$017K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001470831-26-000709) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML